Two isn’t always better than one. Just ask patients caught in the confusion of two national drug codes for the same cholesterol-lowering medicine.
A recent Trump administration decision nudges health plans to do right by patients who struggle with high LDL, or “bad,” cholesterol.
Every 40 seconds, someone in the United States has a heart attack, and every minute, at least one person dies from a heart-related event, according to the Centers for Disease Control and Prevention. Cardiovascular disease killed more than 840,000 Americans in 2016, roughly one death out of three.
What happens when high-risk heart patients can’t get the cholesterol-lowering medicine their doctor prescribes? Heart attacks and strokes, new data confirms.
Sandeep Jauhar’s grandfather was sitting down to lunch with family when he crumpled to the floor. Jeff Kwitowski’s father was on a routine bike ride. Cat Davis Ahmed’s father was enjoying a game of tennis. And Florence Champagne was in an office building when she dropped to her knees, gasping for air and praying for her life.
The barriers and solutions to the current prior-authorization (PA) process at an integrated health system were evaluated.
On April 9, a congressional hearing will explore the impact of pharmacy benefit managers on high drug prices. It’s a connection that many heart patients have learned firsthand.
As the European Union edges toward parliamentary elections, patient advocates have a message for candidates: Prioritize heart health.
Suffered a heart attack? Diagnosed with cardiovascular disease? Confirmed you have genetic high cholesterol? None of that may matter to your health plan.